Trial Profile
ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jun 2019
Price :
$35
*
At a glance
- Drugs Amantadine (Primary)
- Indications Drug-induced dyskinesia
- Focus Registrational; Therapeutic Use
- Acronyms EASE LID 3
- Sponsors Adamas Pharmaceuticals
- 17 Jun 2019 Results published in the Adamas Pharmaceuticals media release
- 17 Jun 2019 According to an Adamas Pharmaceuticals media release, pooled data from EASE LID and EASE LID 3 were presented at the International Association of Parkinsonism and Related Disorders (IAPRD) World Congress, and published in the Journal of Parkinson Disease, online 8th May 2019.
- 09 Oct 2018 Results of pooled phase 3 trials (NCT02274766,NCT02136914 ) assessing Unified Dyskinesia Rating Scale (UDysRS) Parts 1B and Part 3, obtained at baseline and at Week 12, presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders.